

# Association between recent COVID-19 diagnosis on depression and anxiety symptoms among slum residents in Kampala, Uganda

## Authors

Solomon T. Wafula<sup>1,2</sup>, Lesley L. Ninsiima<sup>1</sup>, Hilbert Mendoza<sup>1,3</sup>, John C. Ssempebwa<sup>1</sup>, Florian Walter<sup>4</sup>, David Musoke<sup>1</sup>

## Institutional affiliations

1 Department of Disease Control and Environmental Health, Makerere University School of Public Health, Kampala, Uganda

2 Department of Infectious Disease Epidemiology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

3 Social Epidemiology and Health Policy, Department of Family Medicine and Population Health, University of Antwerp, Antwerp, Belgium

4 Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom

## Correspondence:

Solomon T. Wafula; [swafula@musph.ac.ug](mailto:swafula@musph.ac.ug)

## Contacts

Aisha Nalugya: [aishanalugya18@gmail.com](mailto:aishanalugya18@gmail.com)

Lesley R Ninsiima: [lninsiima04@gmail.com](mailto:lninsiima04@gmail.com)

Hilbert Mendoza: [Hilbert.Mendoza2@uantwerpen.be](mailto:Hilbert.Mendoza2@uantwerpen.be)

John C Ssempebwa: [jsempeps@musph.ac.ug](mailto:jsempeps@musph.ac.ug)

Florian Walter: [florian.walter@manchester.ac.uk](mailto:florian.walter@manchester.ac.uk)

David Musoke: [dmusoke@musph.ac.ug](mailto:dmusoke@musph.ac.ug)

## 1 **Abstract**

### 2 **Background**

3 An increase in mental health problems has been reported since the beginning of the COVID-19  
4 pandemic. However, little is known about the prevalence of depressive and anxiety disorders, and  
5 how recent COVID-19 diagnosis may influence risk of these conditions especially in low-income  
6 settings. In this study, we assessed the association between recent COVID-19 diagnosis and  
7 depressive and anxiety symptoms among residents in an urban slum setting in Uganda.

### 8 **Methods**

9 A cross-sectional study was conducted among 284 individuals in a slum settlement in Kampala,  
10 Uganda between April and May 2022. We assessed generalized anxiety and depression symptoms  
11 using two validated questionnaires. We collected data on sociodemographic characteristics, and  
12 self-reported recent COVID-19 diagnosis (in the previous 30 days). Using a modified Poisson  
13 regression, adjusted for age, sex, gender and household income, we separately provided prevalence  
14 ratios and 95% confidence intervals for the associations between recent COVID-19 diagnosis and  
15 depressive and anxiety symptoms.

### 16 **Results**

17 Overall, 33.8% and 13.4% of the participants met the depression and generalized anxiety screening  
18 criteria respectively. People with recent COVID-19 diagnosis were more likely to be depressed  
19 (53.1%) than those with no recent diagnosis (31.4%). Participants who were recently diagnosed  
20 with COVID-19 reported higher prevalence of anxiety (34.4%) compared to those with no recent  
21 diagnosis of COVID-19 (10.7%). After adjusting for confounding, recent diagnosis with COVID-  
22 19 was associated with depression (PR= 1.60, 95% CI 1.09 – 2.34) and anxiety (PR = 2.83, 95%  
23 CI 1.50 – 5.31) .

### 24 **Conclusion**

25 This study suggests an increased risk of depressive symptoms and GAD in adults following a  
26 COVID-19 diagnosis. We recommend additional mental health support for recently diagnosed  
27 persons. The long-term of COVID-19 on mental health effects also need to be investigated.

28

29 Keywords: COVID-19, depression, anxiety, slum settlement, Uganda

30

31

32

33

34

35

36

## 37 **Introduction**

38 In 2020, the World Health Organization (WHO) declared COVID-19 a pandemic and has since  
39 had detrimental effects on population health and well-being worldwide [1]. The uncertainties and  
40 unpredictable nature of the pandemic resulted in individuals experiencing various forms of mental  
41 health problems such as depression, anxiety, psychosocial dysfunction, dissociation disorders,  
42 substance abuse, and insomnia. It was projected that these effects would be most severe in low-  
43 resourced settings due to constraints related to weak health systems with limited access to mental  
44 health services [2].

45  
46 Low-resourced settings such as slum residences comprise of informal dwelling units which are  
47 poorly constructed, crowded with poor sanitary conditions and environmental pollution [3, 4].  
48 Slum dwellers usually have poor physical and economic access to health care including mental  
49 health care [5]. Most informal settlements comprise an assortment of individuals (e.g., low-income  
50 earners, asylum seekers, refugees), who are at high risk of mental health problems due to multiple  
51 stressors and this may be further aggravated by the COVID-19 pandemic [2]. Due to unfavourable  
52 conditions of unstable income sources, high dependence on daily casual jobs, and threatened  
53 livelihoods and food security [6, 7], slum dwellers may be at elevated risk of experiencing mental  
54 health challenges. A constellation of individual, social and cultural factors that contribute to  
55 psychological distress in informal settings have been highlighted and include trauma, violence,  
56 community insecurity, and healthcare barriers [8]. Mental health among informal settlement  
57 dwellers is understudied at large, including both before and during the COVID-19 pandemic[9].  
58 Available evidence suggests that psychological distress during the pandemic has been high in  
59 various parts of Africa, For example, in a phone-based study in urban areas of Burkina Faso,  
60 Ethiopia, and Egypt, 28% of participants had symptoms of mild, moderate, or severe psychological  
61 distress [10].

62  
63 Evidence from recent epidemics such as SARS, MERS and Ebola poignantly illustrate the  
64 psychosocial impacts of the epidemic and related restrictions. During these epidemics, the fear of

65 infection or death, helplessness, depression, anxiety, social isolation, and stigma are the most  
66 reported psychological manifestations [11]. For example, approximately 15% of individuals  
67 quarantined due to SARS epidemic in the Canadian city of Toronto showed signs of depression  
68 and post-traumatic stress disorder [12]. Similarly, higher prevalences of psychological effects such  
69 as fear, anxiety and depression were reported during the 2013-2016 West Africa Ebola outbreak  
70 [13]. Whereas several studies on the effect of COVID-19 on mental health have been conducted  
71 elsewhere, there was limited evidence regarding the effect of recent diagnosis with COVID-19 on  
72 depression and anxiety, especially among socioeconomically deprived populations such as slum  
73 dwellers. To date, little is known about the burden of mental health conditions disease in urban  
74 slums and related research among slum residents in Uganda and globally [9]. We, therefore, set out  
75 to investigate the association between recent COVID-19 diagnosis and depressive and anxiety  
76 symptoms among residents in an urban slum in Uganda.

## 77 **Methods**

### 78 **Study design and setting**

79 This study used cross-sectional, population-based data from adults (at least 18 years of age)  
80 residing in Bwaise; an urban slum setting in Kampala, Uganda from April to May 2022. Bwaise is  
81 one of Kampala's most densely populated slums, distinguished by mostly informal and  
82 substandard housing and small-scale businesses. It has a high population density, crowded  
83 households, and low socioeconomic status. The study population consisted of adults who had  
84 resided in the area for at least three months.

### 85 **Sampling procedures**

86 A sample of 284 adults from households in the Bwaise slum participated in the study. Sample size  
87 was calculated for the main study[14]. A representative sample of households were selected from  
88 the three parishes in Bwaise. Within each parish, one zone was selected randomly by ballot method,  
89 and at least 93 households were selected from each zone using systematic sampling, with a  
90 sampling interval obtained by dividing the number of households (based on records from the local

91 office (LC)) by the number of households needed in each zone (i.e., divided by 93). Sampling and  
92 interviews started at the LC office and then north direction then clockwise until the target sample  
93 size was realised for each zone. A selected household was replaced by the next household if the  
94 original household had no eligible respondents or did not consent.

## 95 **Study procedures and measures**

96 We organized face-to-face questionnaire interviews with participants through a consenting process  
97 by experienced and trained research assistants. Research assistants with a background training in  
98 health sciences captured participant responses on KoboCollect; a mobile data collection app  
99 (<https://www.kobotoolbox.org/>). We collected information on the exposure (recent COVID-19  
100 diagnosis (in the previous 30 days) and having experiences (diagnosis or death) of a family member  
101 or close friend in the previous 30 days), as well as on covariates; the socio-demographic  
102 characteristics (age, marital status, income, education level, duration of stay), substance use in the  
103 last 30 days (alcohol, smoking, marijuana).

104 The primary outcomes were current depression and generalized anxiety disorder (within the  
105 preceding 2 weeks). Depressive symptoms were assessed using a validated 9-item Patient Health  
106 Questionnaire (PHQ-9) [15] with each item scored as 0 (not at all), 1 (several days), 2 (more than  
107 half the days) and 3 (nearly every day). Thus, the total score of the PHQ-9 can range from 0 to 27.  
108 As previously recommended [16], we used the cutoff score of 10, corresponding with at least a  
109 moderate level of depression. Anxiety was assessed using a 7-item validated Generalized Anxiety  
110 Disorder (GAD-7) tool to screen the presence of generalized anxiety disorder and assess its  
111 severity [17]. The recommended screening cutoff was  $\geq 10$ , corresponding with at least a moderate  
112 anxiety level. Data collection tools were developed following a critical review of existing literature  
113 [18-21].

## 114 **Statistical analysis**

115 Statistical analyses were performed using Stata 14 (Stata Corp, Texas, USA). Descriptive statistics  
116 such as frequencies and percentages were used for categorical data. For continuous data, we used

117 medians and interquartile range. Participant characteristics by depression and anxiety status were  
118 compared using the Wilcoxon rank sum test for non-normally distributed continuous variables  
119 and the Chi-squared test for dichotomous variables. We also performed two separate multivariable  
120 modified Poisson regressions adjusting for age, sex, gender and household income [22] and  
121 producing prevalence ratios (PRs) and corresponding 95% confidence interval (95% CI) for the  
122 association between recent COVID-19 infection and depression and anxiety. All statistical tests  
123 were two-tailed, and statistical significance was assumed when a p-value was  $\leq 0.05$ .

124

## 125 **Results**

### 126 **Background characteristics of participants**

127 In total, 284 participants participated in the study including responding to the PHQ-9 and GAD-  
128 7 questionnaires. Characteristics of all participants are described for depressive and anxiety  
129 disorders determined by PHQ-9 and GAD-7 cutoffs  $\geq 10$ . Most participants were females 85.2%  
130 and had a median age of 29 years (IQR = 24,37). The median depression score based on PHQ-9  
131 was 8 (6,10) while for anxiety, the median score was 6 (4,8) based on the GAD-7. The prevalence  
132 of depression was 33.8% and anxiety was 13.4%, which differed significantly depending on income  
133 ( $p < 0.001$ ) and recent positive COVID-19 diagnosis status ( $p < 0.001$ ) (Table 1).

**Table 1: Characteristics of household participants**

Characteristics	Overall	Current Depressive symptoms			Generalized anxiety disorder		
		No	Yes	p- value	No	Yes	p-value
<b>Total</b>	<b>284</b>	188 (66.2)	96 (33.8)		246 (86.6)	38 (13.4)	
<b>Gender</b>							
Female	242 (85.2)	158 (65.3)	84 (34.7)	0.438	207 (85.5)	35 (14.5)	0.198
Male	42 (14.8)	30 (71.4)	12 (28.6)		39 (92.9)	3 (7.1)	
<b>Age of respondents (in years)</b>							
Median (IQR)	29 (24 ,37)	29 (25,36)	29 (23,38)	0.689 <sup>1</sup>	29 (24, 37)	29 (23, 35)	0.924 <sup>1</sup>
< 30	146 (51.4)	97 (66.4)	49 (33.6)	0.736	126 (86.3)	20 (13.7)	0.794
30 – 45	108 (38.0)	73 (67.6)	35 (32.4)		95 (88.0)	13 (12.0)	
> 45	30 (10.6)	18 (60.0)	12 (40.0)		25 (83.3)	5 (16.7)	
<b>Marital status</b>							
Married or living with partner	136 (47.9)	93 (68.4)	43 (31.6)	0.161	120 (88.2)	16 (11.8)	
Separated	43 (15.1)	23 (53.5)	20 (46.5)		32 (74.4)	11 (25.6)	
Single	105 (37.0)	72 (68.6)	33 (31.4)		94 (89.5)	11 (10.5)	
<b>Education level</b>							
No formal education	25 (8.8)	16 (64.0)	9 (36.0)	0.201	20 (80.0)	5 (20.0)	0.514
Primary	114 (40.1)	69 (60.5)	45 (39.5)		98 (86.0)	16 (14.0)	
Post primary	145 (51.1)	103 (71.0)	42 (29.0)		128 (88.3)	17 (.7)	
<b>Occupation</b>							
Employed	58 (20.4)	131 (67.2)	64 (32.8)	0.490	169 (86.7)	26 (13.3)	0.973
Unemployed	72 (25.4)	48 (66.7)	24 (33.3)		62 (86.1)	10 (13.9)	
Other	17 (6.0)	9 (52.9)	8 (47.1)		15 (88.2)	2 (11.8)	
<b>Owner of the dwelling</b>							
Yes	26 (9.2)	19 (73.1)	7 /26.9)	0.437	23 (88.5)	3 (11.5)	0.772
No	258 (90.8)	169 (65.5)	89 (34.5)		223 (86.4)	35 (13.6)	
<b>Household income (USD)</b>							
Median (IQR)	83.3 (41.7, 125)	83.3 (55.5,125)	83.3 (41.7,125)	0.061 <sup>1</sup>	83.3 (58.3, 125)	41.6 (22.2, 83.3)	<0.001 <sup>1</sup>
< 50	77 27.1	44 (57.1)	33 (42.9)	0.122	55 (71.4)	22 (28.6)	< 0.001
50 – 150	163 57.4	115 (70.6)	48 (29.5)		150 (92.0)	13 (8.0)	
> 150	44 15.5	29 (65.9)	15 (34.1)		41 (93.2)	3 (6.8)	
<b>Duration of residence (years)</b>							
< 5	148 (52.1)	96 (64.9)	52 (35.1)	0.218	125 (84.5)	23 (15.5)	0.366
5 – 10	57 (20.1)	34 (59.7)	23 (40.3)		49 (86.0)	8 (14.0)	



> 10	79 (27.8)	58 (73.4)	21 (26.4)		72 (91.1)	7 (8.9)	
<b>COVID-19</b>							
<b>Diagnosed with COVID-19 in last 30 days</b>	252 (88.7)	173 (68.7)	79 (31.4)	0.014	225 (89.3)	27 (10.7)	<0.001
<b>:No</b>							
Yes	32 (11.3)	15 (46.9)	17 (53.1)		21 (65.6)	11 (34.4)	
<b>Had family member or close friend who suffered or died from COVID-19 in the previous 30 days: No</b>	220 (77.5)	147 (66.8)	73 (33.2)	0.682	188 (85.5)	32 (14.6)	0.285
yes	64 (22.5)	41 (64.1)	23 (35.9)		58 (90.6)	6 (9.4)	
<b>Substance use in last 30 days</b>							
Alcohol use: No	175 (61.6)	120 (68.6)	55 (31.4)	0.284	159 (90.9)	16 (9.1)	0.008
Yes	109 (38.4)	68 (62.4)	41 (37.6)		87 (79.8)	22 (20.2)	
Smoking: No	243 (85.6)	166 (68.3)	77 (31.7)	0.067	215 (88.5)	28 (11.5)	0.025
Yes	41 (14.4)	22 (53.7)	19 (46.3)		31 (75.6)	10 (24.4)	
Marijuana: No	265 (93.3)	176 (66.4)	89 (33.6)	0.772	229 (86.4)	36 (13.6)	0.705
Yes	19 (6.7)	12 (63.2)	7 (36.8)		17 (89.5)	2 (10.5)	
<b>Have children under 5 years: No</b>	128 (45.1)	86 (67.2)	42 (32.8)	0.749	117(91.4)	11 (8.6)	0.032
Yes	156 (54.9)	102 (65.4)	54 (34.6)		129 (82.7)	27 (17.3)	

135  
136  
137

<sup>1</sup> p-value based on the Wilcoxon rank sum test; other p-values based on Pearson chi-square statistics.

138 **Association between recent COVID-19 diagnosis and depressive symptoms**

139

140 In unadjusted analysis, there was a significant association between recent SARS-COV-2 infection

141 with household income and smoking in households. After adjusting for age, gender and income,

142 recent COVID-19 diagnosis was positively associated with current depressive symptoms (PR=

143 1.60, 95% CI 1.09 – 2.34) (Table 2).

144

145 **Table 2: Association between recent COVID-19 diagnosis and depressive symptoms**

Attributes	Current depressive symptoms			
	Unadjusted analysis		Adjusted analysis	
	PR (95 % CI)	p-value	PR (95 % CI)	p-value
<b><i>Sociodemographic characteristics</i></b>				
<b>Gender</b>				
Female	1			
Male	0.82 (0.45 – 1.51)	0.454	0.83 (0.49 – 1.39)	0.470
<b>Age of respondents (in years)</b>	1.00 (0.98 – 1.02)	0.872	1.00 (0.98 – 1.01)	0.896
<b>Marital status</b>				
Married or with partner	1		1	
Separated	1.47 (0.86 – 2.50) +	0.062	1.25 (0.81 – 1.92)	0.312
Single	0.99 (0.63 – 1.56)	0.975	0.92(0.62 – 1.36)	0.665
<b>Education level</b>				
No formal education	1			
Primary	1.09 (0.54 – 2.24)	0.752		
Post primary	0.80 (0.39 – 1.65)	0.464		
<b>Occupation</b>				
Employed	1		1	
Unemployed	1.01 (0.69 – 1.49)	0.937	0.98 (0.65 – 1.48)	0.931
Other	1.43 (0.83 – 2.47)	0.194	1.41 (0.78 – 2.55)	0.253
<b>Owner of the dwelling:</b>	1.28 (0.59 – 2.76)	0.459		
<b>Length of stay (years)</b>				
< 5	1			
5 - 10	1.14 (0.70 – 1.88)	0.481		
>10	0.76 (0.46 – 1.26)	0.201		
<b>Household income (USD)</b>				
< 50	1		1	
50 – 150	0.69 (0.48 – 0.98)	<b>0.036</b>	0.80 (0.55 – 1.15)	0.224
> 150	0.80 (0.49 – 1.29)	0.356	0.83 (0.51 – 1.36)	0.457
<b><i>COVID-19 experiences</i></b>				
Diagnosed with COVID-19 in the last 30 days	1.69 (1.01 – 2.86) *	<b>0.006</b>	1.60 (1.09 – 2.34)	<b>0.016</b>
Family or close friend suffered or died from COVID-19 in the previous 30 days	1.08 (0.67 – 1.73)	0.679		
<b><i>Psychoactive substance uses</i></b>				
Alcohol use	1.20 (0.80 – 1.79)	0.281		
Regular smoking	1.46 (0.89 – 2.42)	<b>0.049</b>	1.29 (0.85 – 1.96)	0.225
Marijuana or cannabis use	1.09 (0.51 – 2.36)	0.768		
<b>Have children under 5</b>	1.05 (0.70 – 1.58)	0.750		

146

147

148

149 **Association between recent COVID-19 diagnosis and generalized anxiety disorder**

150

151 In adjusted analysis, participants who had been diagnosed with COVID-19 within 30 days of the  
152 survey had a 2.8 times higher risk of anxiety compared to their counterparts (PR = 2.83, 95%CI  
153 1.50 – 5.31). Higher monthly incomes (i.e. USD 50 – 150 (PR = 0.38, 95%CI (0.19 – 0.76) and  
154 USD > 150 (PR = 0.30, 95%CI (0.11 – 0.87)) were associated with lower risk of anxiety symptoms  
155 compared to those who earned less than USD 50. The likelihood of meeting anxiety screening  
156 criteria was 2.23 times higher among particular who reported regularly drinking alcohol compared  
157 to those with no/limited alcohol consumption (PR = 2.23, 95CI 1.12 – 4.42) (Table 3).

158

159 **Table 3: Association between recent COVID-19 diagnosis and anxiety disorder**

Attributes	Generalized Anxiety disorder			
	Unadjusted analysis		Adjusted analysis	
	PR (95 % CI)	p-value	PR (95 % CI)	p-value
<b><i>Sociodemographic characteristics</i></b>				
<b>Gender</b>				
Female	1		1	
Male	0.49 (0.16 – 1.54)	0.223	0.57 (0.21 – 1.52)	0.260
<b>Age of respondents (in years)</b>	1.01 (0.98 – 1.03)	0.592	1.02 (0.98 – 1.05)	0.347
<b>Marital status</b>				
Married or with partner	1		1	
Separated	2.17 (1.01 – 4.68)	<b>0.027</b>	1.56 (0.72 – 3.42)	0.262
Single	0.89 (0.41 – 1.92)	0.754	0.82 (0.41 – 1.63)	0.567
<b>Education level</b>				
No formal education	1			
Primary	0.70 (0.26 – 1.92)	0.444		
Post primary	0.59 (0.22 – 1.59)	0.247		
<b>Occupation</b>				
Formal or informal employment	1			
Unemployed	1.04 (0.52 – 2.05)	0.906		
Other	0.88 (0.22 – 3.41)	0.856		
<b>Owner of the dwelling: No</b>				
Length of stay				
< 5 years	1		1	
5 - 10	0.90 (0.41 – 2.01)	0.789	1.14 (0.53 – 2.44)	0.733
>10	0.57 (0.24 – 1.33)	0.170	0.53 (0.21 – 1.33)	0.176
<b>Household income (USD)</b>				
< 50	1			
50 – 150	0.28 (0.14 – 0.52)	<b>0.001</b>	0.38 (0.19 – 0.76)	<b>0.006</b>
> 150	0.24 (0.08 – 0.75)	<b>0.015</b>	0.30 (0.11 – 0.87)	<b>0.026</b>
<b><i>COVID-19 experiences</i></b>				
<b>Diagnosed with COVID-19 in the last 30 days</b>	3.21 (1.76 – 5.83)	<b>&lt;0.001</b>	2.83 (1.50 – 5.31)	<b>0.001</b>
<b>Family or close friend suffered or died from COVID-19 in the previous 30 days</b>	0.64 (0.27 – 1.54)	0.298		
<b><i>Psychoactive substance use in the last 30 days</i></b>				
Alcohol	2.21 (1.16 – 4.20)	<b>0.010</b>	2.23 (1.12 – 4.42)	<b>0.022</b>
Smoking	2.12 (1.03 – 4.35)	<b>0.022</b>	1.21 (0.52 – 2.85)	0.662
Marijuana	0.77 (0.19 – 3.22)	0.711		
<b>Have children under 5</b>	2.01 (1.00 – 4.06)	<b>0.038</b>	1.93 (0.98 – 3.82)	0.058

## 160 Discussion

161  
162 In this community-based study, we examined the prevalence of depressive symptoms and anxiety  
163 and their association with recent COVID-19 diagnosis among adult slum dwellers in Kampala,  
164 Uganda. Our findings highlight the challenges that individuals affected by COVID-19 face and are  
165 consistent with the larger literature on the impact of COVID-19 on mental health in the general  
166 population. In this study, a recent COVID-19 diagnosis was associated with both depression and  
167 anxiety. For instance, it increased the likelihood of depressive symptoms by 60%. For GAD, the  
168 prevalence was 2.8 times higher than for those who did not have a recent infection after adjusting  
169 for age, gender, household income and use of psychoactive substances.

170 Our study results revealed a high prevalence of anxiety and depression among participants (13.4%  
171 and 33.8%, respectively). High levels of depression and anxiety raise concerns about the capacity  
172 of mental healthcare systems to respond during the pandemic. The prevalence of depression in  
173 this study was higher than national pre-pandemic levels of 29.3%[23]. In addition to studies in the  
174 general adult population in Uganda, there is evidence that mental health was significantly affected  
175 by the COVID-19 pandemic even when not directly affected by the infection [24]. In the previous  
176 study, the prevalence rates were reported to be in excess of 80% for depression and 90% for  
177 anxiety. Although outcome measures are not directly comparable to our study, the reported rates  
178 appear worryingly high. As noted in that study, several limitations related to the data collection  
179 might have artificially increased the prevalence rates. However, the study underlines the  
180 significance of the mental health impact attributed to COVID-19 and related restrictions. Our  
181 findings support new evidence from other LMICs on the state of mental health during the  
182 pandemic. For instance, a recent study conducted in a socially and economically comparable setting  
183 in Kenya, reported elevated rates of depression (34.1%) and GAD (14.0%) [2] while in Bangladesh,  
184 the estimated prevalence of depression was 33.0%[25]. A further study from the United  
185 Kingdom[26] has compared pre- and post-COVID-19 rates of psychological distress and has  
186 shown that deterioration of mental health did not recover after COVID-19 restrictions were eased.

187 Further evidence indicates mental health problems among adults, especially during a health crisis,  
188 impact negatively on child developmental and behavioural outcomes[27]. The implication is that  
189 children by parents/guardians with such environments and backgrounds may be at elevated risk  
190 to experience various cognitive, behavioural, and emotional problems later in life if the problem is  
191 not addressed [28].

192 Although several studies have highlighted the elevated risk of mental health disorders and  
193 psychological distress during the COVID-19 pandemic, there seems to be limited research  
194 focusing specifically on how being recently diagnosed with COVID-19 affects individuals' mental  
195 health. In our study, recently diagnosed (< 30 days) participants were 1.5 times and 2.8 times more  
196 likely to be diagnosed to have depression and anxiety respectively compared to their counterparts.  
197 In line with these findings, evidence from the United States (23) showed that experiencing a  
198 COVID-19 infection was associated with an increased risk of common mental disorders such as  
199 anxiety and depression in the acute phase of the infection. This is also in agreement with multiple  
200 other studies reporting an elevation in mental health problems following infection [29-32]. Our  
201 study is, to our knowledge, this is one of the first studies to investigate the influence of recent  
202 COVID-19 diagnosis on depression and anxiety in Uganda and reinforces the fact that the month  
203 following an infection seems to be associated more strongly with depressive symptoms and anxiety  
204 than experiencing a COVID-19 infection at any point in the past[33]. A possible explanation for  
205 these findings is that additional stressors related to the impact of COVID-19 infections such as  
206 financial problems, isolation from others, grief and worries about others could contribute to the  
207 experience of common mental health problems. However, studies have suggested that underlying  
208 biological mechanisms could also explain the increase in the prevalence of mental disorders [34,  
209 35]. It is well established that the mechanisms, predominantly driven by the body's immune  
210 response and associated cytokine activity can affect the neurological structures of patients. It is  
211 therefore reasonable to suggest that these changes could contribute to the observed effects on  
212 mental health. However, these mechanisms are not fully understood and require further research.

## 213 **Limitations**

214 Although our study is the first to examine the association between recent COVID-19 diagnosis  
215 and depressive symptoms and GAD in an informal settlement in Uganda, it had several limitations.  
216 First of all, a recent COVID-19 diagnosis was self-reported (as told to participants by medical  
217 practitioners after tests) and we could not validate this. It is possible that participants misclassified  
218 themselves as not having a COVID-19 infection because they were not tested or diagnosed during  
219 the study period (especially if they were asymptomatic). Second, we only collected data on a limited  
220 set of confounding variables, which, coupled with the relatively small sample size, may have  
221 hampered the robustness of our findings because we were unable to account for all relevant  
222 confounders. Thirdly, we assessed mental health cross-sectionally which limits our ability to test  
223 changes in prevalence over time and whether the associations changed as time since diagnosis  
224 increased and also as the pandemic progressed. However, considering that our findings correspond  
225 with the wider literature we are confident that despite unmeasured confounding, this association  
226 would still hold even if we were to adjust for further covariates. Longitudinal studies may be  
227 needed in future to assess the effect of COVID-19 diagnosis on mental health over time.

## 228 **Conclusion**

229 Overall, the study suggests an elevated risk for depressive symptoms and GAD among adults  
230 within 30 days following COVID-19 diagnosis. These findings suggest that additional support is  
231 required to address this burden and ensure that people receive mental /emotional treatment when  
232 necessary. Although we evaluated the effect of COVID-19 diagnosis on mental health within 30  
233 days, long-term effects are possible; therefore, future research should evaluate the long-term  
234 consequences of COVID-19 infections in LMICS.

235

236

237

238

239 **Declarations**

240 **Acknowledgements**

241 We appreciate the local authorities for administrative support as well as the research assistants and  
242 the participants for without which this study would not have been possible.

243 **Contributors**

244 STW, MH and DM conceived and designed the study, STW supervised data collection, LLN,  
245 STW, HM and FW analyzed the data and wrote the first draft of the manuscript. STW, HM, JCS,  
246 FW and DM provided a critical review of the manuscript. All authors contributed to the  
247 interpretation of the results, reviewed and editing of the manuscript and approved the final version  
248 for publication.

249 **Funding**

250 This work was supported by Makerere University School of Public Health under the Small  
251 Grants Programme (MakSPH-GRCB/18-19/01/02 to STW). The funders had no role in study  
252 design, data collection and analysis, decision to publish, or preparation of the manuscript.

253

254 **Data availability statement**

255 All relevant data are available from within the manuscript as well as a supplementally information  
256 file.

257

258 **Declaration of interests**

259 The authors have declared that no competing interests exist

260 **Ethical consideration**

261 Ethical approval was obtained from Makerere University School of Public Health Higher Degrees  
262 Research and Ethics Committee (HDREC: Ref No. SPH-2021-99) and Uganda National Council  
263 of Science and Technology (UNCST: Ref No. SS996ES). The Kampala Capital City Authority  
264 gave permission for the study's implementation, provided advise and support with planning of  
265 study activities. We followed principles of the Helsinki declaration and written informed consent  
266 was obtained from each participant.

## 267 **References**

- 268 1. Logie CH, Berry I, Okumu M, Loutet M, McNamee C, Hakiza R, et al. The prevalence  
269 and correlates of depression before and after the COVID-19 pandemic declaration among  
270 urban refugee adolescents and youth in informal settlements in Kampala, Uganda: A  
271 longitudinal cohort study. *Ann Epidemiol.* 2022;66:37-43. Epub 2021/11/18. doi:  
272 10.1016/j.annepidem.2021.11.005. PubMed PMID: 34785396; PubMed Central PMCID:  
273 PMCPMC8590831.
- 274 2. Angwenyi V, Kabue M, Chongwo E, Mabrouk A, Too EK, Odhiambo R, et al. Mental  
275 Health during COVID-19 Pandemic among Caregivers of Young Children in Kenya's Urban  
276 Informal Settlements. A Cross-Sectional Telephone Survey. *International Journal of*  
277 *Environmental Research and Public Health.* 2021;18(19):10092. PubMed PMID:  
278 doi:10.3390/ijerph181910092.
- 279 3. Khatua S. Density, distancing, informal settlements and the pandemic. *Economic and*  
280 *Political Weekly.* 2020;55(20):7-8.
- 281 4. Cicione A, Walls RS, Kahanji C. Experimental study of fire spread between multiple full  
282 scale informal settlement dwellings. *Fire safety journal.* 2019;105:19-27.
- 283 5. Joulaei H, Bhuiyan AR, Sayadi M, Morady F, Afsar Kazerooni P. Slums' access to and  
284 coverage of primary health care services: a cross-sectional study in shiraz, a metropolis in  
285 southern iran. *Iran J Med Sci.* 2014;39(2 Suppl):184-90. Epub 2014/04/23. PubMed PMID:  
286 24753641; PubMed Central PMCID: PMCPMC3993042.
- 287 6. Kimani-Murage EW, Schofield L, Wekesah F, Mohamed S, Mberu B, Ettarh R, et al.  
288 Vulnerability to Food Insecurity in Urban Slums: Experiences from Nairobi, Kenya. *Journal of*  
289 *Urban Health.* 2014;91(6):1098-113. doi: 10.1007/s11524-014-9894-3.
- 290 7. Nyadera IN, Onditi F. COVID-19 experience among slum dwellers in Nairobi: A double  
291 tragedy or useful lesson for public health reforms? *International Social Work.* 2020;63(6):838-  
292 41. doi: 10.1177/0020872820944997.
- 293 8. Silove D, Ventevogel P, Rees S. The contemporary refugee crisis: an overview of  
294 mental health challenges. *World Psychiatry.* 2017;16(2):130-9. Epub 2017/05/13. doi:  
295 10.1002/wps.20438. PubMed PMID: 28498581; PubMed Central PMCID: PMCPMC5428192.
- 296 9. Ezeh A, Oyebode O, Satterthwaite D, Chen YF, Ndugwa R, Sartori J, et al. The history,  
297 geography, and sociology of slums and the health problems of people who live in slums.  
298 *Lancet.* 2017;389(10068):547-58. Epub 2016/10/21. doi: 10.1016/s0140-6736(16)31650-6.  
299 PubMed PMID: 27760703.
- 300 10. Workneh F, Wang D, Millogo O, Worku A, Chukwu A, Lankoande B, et al. Knowledge  
301 and Practice Related to COVID-19 and Mental Health among Adults in Sub-Saharan Africa. *The*  
302 *American Journal of Tropical Medicine and Hygiene.* 2021;105(2):351-62. doi:  
303 10.4269/ajtmh.21-0219.
- 304 11. Khan KS, Mamun MA, Griffiths MD, Ullah I. The Mental Health Impact of the COVID-  
305 19 Pandemic Across Different Cohorts. *Int J Ment Health Addict.* 2022;20(1):380-6. Epub  
306 2020/08/25. doi: 10.1007/s11469-020-00367-0. PubMed PMID: 32837440; PubMed Central  
307 PMCID: PMCPMC7347045 interest.
- 308 12. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and  
309 psychological effects of quarantine, Toronto, Canada. *Emerg Infect Dis.* 2004;10(7):1206-12.  
310 Epub 2004/08/25. doi: 10.3201/eid1007.030703. PubMed PMID: 15324539; PubMed Central  
311 PMCID: PMCPMC3323345.
- 312 13. Van Bortel T, Basnayake A, Wurie F, Jambai M, Koroma AS, Muana AT, et al.  
313 Psychosocial effects of an Ebola outbreak at individual, community and international levels.



- 314 Bull World Health Organ. 2016;94(3):210-4. Epub 2016/03/12. doi: 10.2471/blt.15.158543.  
315 PubMed PMID: 26966332; PubMed Central PMCID: PMC4773931.
- 316 14. Wafula ST, Nalugya A, Mendoza H, Kansime WK, Ssekamatte T, Walekhwa AW, et al.  
317 Indoor air pollutants and respiratory outcomes among residents of an informal urban setting  
318 in Uganda: a cross-sectional study. medRxiv. 2022:2022.07.28.22278151. doi:  
319 10.1101/2022.07.28.22278151.
- 320 15. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity  
321 measure. Journal of general internal medicine. 2001;16(9):606-13.
- 322 16. Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with  
323 the Patient Health Questionnaire (PHQ-9): a meta-analysis. Canadian Medical Association  
324 Journal. 2012;184(3):E191. doi: 10.1503/cmaj.110829.
- 325 17. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized  
326 anxiety disorder: the GAD-7. Archives of internal medicine. 2006;166(10):1092-7.
- 327 18. Jafta N, Barregard L, Jeena PM, Naidoo RN. Indoor air quality of low and middle income  
328 urban households in Durban, South Africa. Environmental Research. 2017;156:47-56. doi:  
329 <https://doi.org/10.1016/j.envres.2017.03.008>.
- 330 19. Heseltine E, Rosen J. WHO guidelines for indoor air quality: dampness and mould.  
331 2009.
- 332 20. Rumchev K, Zhao Y, Spickett J. Health risk assessment of indoor air quality,  
333 socioeconomic and house characteristics on respiratory health among women and children  
334 of Tirupur, South India. International journal of environmental research and public health.  
335 2017;14(4):429.
- 336 21. Nadali A, Arfaenia H, Asadgol Z, Fahiminia M. Indoor and outdoor concentration of  
337 PM10, PM2.5 and PM1 in residential building and evaluation of negative air ions (NAIs) in  
338 indoor PM removal. Environmental Pollutants and Bioavailability. 2020;32(1):47-55.
- 339 22. Zou G. A modified poisson regression approach to prospective studies with binary  
340 data. Am J Epidemiol. 2004;159(7):702-6. Epub 2004/03/23. doi: 10.1093/aje/kwh090.  
341 PubMed PMID: 15033648.
- 342 23. Kaggwa MM, Najjuka SM, Bongomin F, Mamun MA, Griffiths MD. Prevalence of  
343 depression in Uganda: A systematic review and meta-analysis. PLOS ONE.  
344 2022;17(10):e0276552. doi: 10.1371/journal.pone.0276552.
- 345 24. Najjuka SM, Checkwech G, Olum R, Ashaba S, Kaggwa MM. Depression, anxiety, and  
346 stress among Ugandan university students during the COVID-19 lockdown: an online survey.  
347 Afr Health Sci. 2021;21(4):1533-43. Epub 2022/03/15. doi: 10.4314/ahs.v21i4.6. PubMed  
348 PMID: 35283951; PubMed Central PMCID: PMC4773931.
- 349 25. Mamun MA, Sakib N, Gozal D, Bhuiyan AI, Hossain S, Bodrud-Doza M, et al. The COVID-  
350 19 pandemic and serious psychological consequences in Bangladesh: A population-based  
351 nationwide study. J Affect Disord. 2021;279:462-72. Epub 2020/10/30. doi:  
352 10.1016/j.jad.2020.10.036. PubMed PMID: 33120247; PubMed Central PMCID:  
353 PMC4773931.
- 354 26. Patel K, Robertson E, Kwong ASF, Griffith GJ, Willan K, Green MJ, et al. Psychological  
355 Distress Before and During the COVID-19 Pandemic Among Adults in the United Kingdom  
356 Based on Coordinated Analyses of 11 Longitudinal Studies. JAMA Netw Open.  
357 2022;5(4):e227629. Epub 2022/04/23. doi: 10.1001/jamanetworkopen.2022.7629. PubMed  
358 PMID: 35452109.
- 359 27. Laurenzi CA, Hunt X, Skeen S, Sundin P, Weiss RE, Kosi V, et al. Associations between  
360 caregiver mental health and young children's behaviour in a rural Kenyan sample. Glob Health

- 361 Action. 2021;14(1):1861909. Epub 2021/01/06. doi: 10.1080/16549716.2020.1861909.  
362 PubMed PMID: 33397222; PubMed Central PMCID: PMC7801103.
- 363 28. Shumba C, Maina R, Mbuthia G, Kimani R, Mbugua S, Shah S, et al. Reorienting  
364 Nurturing Care for Early Childhood Development during the COVID-19 Pandemic in Kenya: A  
365 Review. *Int J Environ Res Public Health*. 2020;17(19). Epub 2020/10/01. doi:  
366 10.3390/ijerph17197028. PubMed PMID: 32992966; PubMed Central PMCID:  
367 PMC7579158.
- 368 29. Ahmed GK, Khedr EM, Hamad DA, Meshref TS, Hashem MM, Aly MM. Long term  
369 impact of Covid-19 infection on sleep and mental health: A cross-sectional study. *Psychiatry*  
370 *Res*. 2021;305:114243. Epub 2021/10/22. doi: 10.1016/j.psychres.2021.114243. PubMed  
371 PMID: 34673325; PubMed Central PMCID: PMC8507572.
- 372 30. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and  
373 psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study  
374 using electronic health records. *The Lancet Psychiatry*. 2021;8(5):416-27. doi: 10.1016/S2215-  
375 0366(21)00084-5.
- 376 31. Thompson EJ, Stafford J, Moltrecht B, Huggins CF, Kwong ASF, Shaw RJ, et al.  
377 Psychological distress, depression, anxiety, and life satisfaction following COVID-19 infection:  
378 evidence from 11 UK longitudinal population studies. *The Lancet Psychiatry*. 2022;9(11):894-  
379 906. doi: 10.1016/S2215-0366(22)00307-8.
- 380 32. Magnúsdóttir I, Lovik A, Unnarsdóttir AB, McCartney D, Ask H, Kõiv K, et al. Acute  
381 COVID-19 severity and mental health morbidity trajectories in patient populations of six  
382 nations: an observational study. *The Lancet Public Health*. 2022;7(5):e406-e16. doi:  
383 10.1016/S2468-2667(22)00042-1.
- 384 33. Klaser K, Thompson EJ, Nguyen LH, Sudre CH, Antonelli M, Murray B, et al. Anxiety and  
385 depression symptoms after COVID-19 infection: results from the COVID Symptom Study app.  
386 *Journal of Neurology, Neurosurgery & Psychiatry*. 2021;92(12):1254. doi:  
387 10.1136/jnnp-2021-327565.
- 388 34. Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. Dysregulation of  
389 brain and choroid plexus cell types in severe COVID-19. *Nature*. 2021;595(7868):565-71. Epub  
390 2021/06/22. doi: 10.1038/s41586-021-03710-0. PubMed PMID: 34153974; PubMed Central  
391 PMCID: PMC8400927.
- 392 35. Etter MM, Martins TA, Kulsvehagen L, Pössnecker E, Duchemin W, Hogan S, et al.  
393 Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and  
394 neurodegeneration: a prospective cross-sectional study. *Nat Commun*. 2022;13(1):6777.  
395 Epub 2022/11/10. doi: 10.1038/s41467-022-34068-0. PubMed PMID: 36351919.  
396  
397